The ongoing telmisartan alone and in combination with ramipril global endpoint trial program (Q35143225)

6 August 2017

title

The ongoing telmisartan alone and in combination with ramipril global endpoint trial program (English)

1 reference

6 August 2017

Thomas Unger

1 reference

6 August 2017

language of work or name

English

0 references

publication date

1 May 2003

1 reference

American Journal of Cardiology

6 August 2017

published in

1 reference

6 August 2017

1 reference

6 August 2017

issue

10A

1 reference

6 August 2017

page(s)

28G-34G

1 reference

Angiotensin II and trials of cardiovascular outcomes

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900230-3

Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900230-3

Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial--the Losartan Heart Failure Survival Study ELITE II.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900230-3

Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900230-3

Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900230-3

Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900230-3

Adverse effects of the angiotensin-converting enzyme inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900230-3

Angiotensin II receptor antagonists

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900230-3

A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900230-3

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900230-3

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900230-3

The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900230-3

Pathophysiologic and therapeutic importance of tissue ACE: a consensus report

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900230-3

Chymase-dependent angiotensin II forming systems in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900230-3

Neurohormonal modulation in cardiovascular disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900230-3

The role of the renin-angiotensin system in the development of cardiovascular disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900230-3

Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900230-3

Angiotensin II Increases Macrophage-mediated Modification of Low Density Lipoprotein via a Lipoxygenase-dependent Pathway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900230-3

Angiotensin II type 1 receptor-mediated peroxide production in human macrophages

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900230-3

Angiotensin II induces migration and Pyk2/paxillin phosphorylation of human monocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900230-3

Angiotensin II–Induced Leukocyte Adhesion on Human Coronary Endothelial Cells Is Mediated by E-Selectin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900230-3

Angiotensin AT1 receptor antagonist irbesartan decreases lesion size, chemokine expression, and macrophage accumulation in apolipoprotein E-deficient mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900230-3

Angiotensin II stimulates synthesis of vascular smooth muscle cell proteoglycans with enhanced low density lipoprotein binding properties

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900230-3

Effect of captopril and losartan on blood pressure and accumulation of LDL and fibrinogen by aortic wall and other tissues in normotensive and hypertensive rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900230-3

Valsartan improves fibrinolytic balance in atherosclerotic rabbits.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900230-3

Angiotensin-Converting Enzyme Inhibitors Downregulate Tissue Factor Synthesis in Monocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900230-3

Angiotensin AT1 receptor over-expression in hypercholesterolaemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900230-3

Statin-sensitive dysregulated AT1 receptor function and density in hypercholesterolemic men

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900230-3

Comparison of telmisartan with lisinopril in patients with mild-to-moderate hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900230-3

Comparison of 26-week efficacy and tolerability of telmisartan and atenolol, in combination with hydrochlorothiazide as required, in the treatment of mild to moderate hypertension: a randomized, multicenter study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900230-3

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900230-3

ABPM comparison of the antihypertensive profiles of the selective angiotensin II receptor antagonists telmisartan and losartan in patients with mild-to-moderate hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900230-3

Circadian variation in the frequency of onset of acute myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900230-3

Meta-analysis of the morning excess of acute myocardial infarction and sudden cardiac death

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900230-3

Circadian variation in the incidence of sudden cardiac death in the Framingham Heart Study population

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900230-3

Increased onset of sudden cardiac death in the first three hours after awakening

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900230-3

Morning increase in onset of ischemic stroke

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900230-3

Circadian variation in acute ischemic stroke: a hospital-based study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900230-3

The 24-hour blood pressure pattern: does it have implications for morbidity and mortality?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900230-3

Prognostic value of ambulatory blood pressure : current evidence and clinical implications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900230-3

Ramipril: a review of its use in the prevention of cardiovascular outcomes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900230-3

Effects of ramipril and vitamin E on atherosclerosis: the study to evaluate carotid ultrasound changes in patients treated with ramipril and vitamin E (SECURE).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900230-3

Effects of ramipril on coronary events in high-risk persons: results of the Heart Outcomes Prevention Evaluation Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900230-3

Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the angiotensin-converting enzyme inhibitor ramipril

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900230-3

Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900230-3

Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900230-3

10.1016/S0002-9149(03)00230-3

7 January 2021

Identifiers

DOI

1 reference

release_qlzfwo54nvc65dtbmjtvwqj3xa

6 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/qlzfwo54nvc65dtbmjtvwqj3xa

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference